FDA accepts Pfizer/Priovant’s brepocitinib NDA with Priority Review for dermatomyositis

Priovant Therapeutics, a clinical-stage biotechnology company headquartered in Durham, North Carolina, and a subsidiary of Roivant Sciences (Nasdaq: ROIV), announced that the US FDA has accepted its New Drug Application (NDA) for brepocitinib and granted Priority Review for the treatment of dermatomyositis (DM). Brepocitinib is an oral, once-daily small molecule that functions as a dual selective inhibitor of tyrosine kinase 2 (TYK2) and Janus kinase 1 (JAK1). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date in Q3 2026, and Priovant expects a US launch at the end of September 2026. If approved, brepocitinib would be the first targeted therapy cleared for dermatomyositis.

Notably, Priovant was established by Pfizer and Roivant in 2021 and licensed global development rights and US and Japan commercial rights to brepocitinib. Pfizer retains a 25% equity stake in Priovant.

Priority Review reduces the FDA’s target review clock from the standard 10 months to approximately 6 months from the date of filing acceptance. The designation is reserved for applications where the proposed drug, if approved, would provide improvements in the safety or effectiveness of treating a serious condition relative to available therapies. In addition to Priority Review, brepocitinib has previously received both Breakthrough Therapy Designation (BTD) and Orphan Drug Designation (ODD) from the FDA for dermatomyositis.

Brepocitinib’s Phase III VALOR trial

The Priority Review designation was supported by results from the Phase III VALOR study (NCT05437263), a global, placebo-controlled trial that enrolled 241 adults with dermatomyositis across 90 sites comparing brepocitinib to placebo. The primary endpoint was the myositis Total Improvement Score (TIS) evaluated at Week 52.

Brepocitinib 30 mg met the primary endpoint, demonstrating a statistically significant difference versus placebo on TIS at Week 52 (mean TIS 46.5 vs. 31.2; p=0.0002). Separation from placebo was observed as early as Week 4 and sustained at every subsequent visit through the end of the 52-week double-blind period. The 30 mg dose also met all nine key secondary endpoints, which spanned measures of skin disease, muscle disease, and steroid sparing.

VALOR is the longest and largest interventional trial conducted in dermatomyositis and the first to produce a positive result over a 52-week placebo-controlled period. On safety, serious infections were increased in the brepocitinib 30 mg arm compared to placebo; these events resolved with medical management, and treatment was completed in most cases.

Drug origin and development platform

Brepocitinib was originally discovered by Pfizer, where it carried the internal designation PF-06700841. In December 2021, Roivant Sciences acquired global development and commercialization rights to the molecule from Pfizer through a licensing deal involving upfront and milestone payments. Priovant Therapeutics, a dedicated Roivant subsidiary, assumed responsibility for clinical development and regulatory filings.

Beyond dermatomyositis, brepocitinib is being evaluated in a Phase III program in non-infectious, non-anterior uveitis (NCT06431373), with 371 subjects enrolled and a primary endpoint of time to treatment failure up to Week 48. The company also reported positive Phase II data in cutaneous sarcoidosis (BEACON study), with a Phase III study planned to begin in calendar year 2026. Through dual TYK2/JAK1 inhibition, brepocitinib suppresses cytokines linked to autoimmunity, including type I interferon (IFN), type II IFN, interleukin-6 (IL-6), IL-12, and IL-23, via a single oral agent.

Dermatomyositis is an autoimmune condition characterized by muscle weakness, skin disease, and chronic inflammation. Patients frequently depend on high-dose corticosteroids and broad immunosuppressants, which carry cumulative organ toxicity and contribute to comorbidities. No targeted therapies are currently approved for the condition.